Impact Events
More| Date | Lead Company | Event | Type | Approval Change | Approval Likelihood |
|---|---|---|---|---|---|
| 10/9/26 | Raynovent Biotech | RAY1225 for Diabetes Mellitus, Type II | Subscribers Only | Subscribers Only | Subscribers Only |
| 10/9/26 | Sagimet (SGMT) | denifanstat for Acne | Subscribers Only | Subscribers Only | Subscribers Only |
| 10/8/26 | Bristol Myers Squibb (BMY) | Zenbexus for Multiple Myeloma (MM) | Subscribers Only | Subscribers Only | Subscribers Only |
| 10/7/26 | MimiVax | SurVaxM for Brain Cancer (Malignant Glioma; AA and glioblastoma) | Subscribers Only | Subscribers Only | Subscribers Only |
| 10/6/26 | ArriVent (AVBP) | Ivesa for Non-Small Cell Lung Cancer (NSCLC) | Subscribers Only | Subscribers Only | Subscribers Only |
Upcoming Catalysts
More| Expected Date Range | Lead Company | Drug | Expected Catalyst |
|---|---|---|---|
| 07/31/2025 | Subscribers Only | Subscribers Only | Regulatory - sNDA/sBLA Filing |
| 07/31/2025 | Subscribers Only | Subscribers Only | Regulatory - IND/CTA Filing |
| 10/28/2025 | Subscribers Only | Subscribers Only | Company - Analyst/R&D Update |
| 10/31/2025 | Subscribers Only | Subscribers Only | Company - Analyst/R&D Update |
| 11/11/2025 | Subscribers Only | Subscribers Only | Company - Analyst/R&D Update |